文献速递MDS 与骨髓增殖性肿瘤

合并症与恶性肿瘤对骨髓增生异常综合征患者生存的负面影响:一项基于人群的研究

Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study.
PubMed 文献 · Blood Adv · 2021-01-01

该研究基于荷兰弗里斯兰省HemoBase登记库,纳入2005至2017年确诊的291例MDS患者,随访至2019年6月。中位总生存期为25.3个月(95%CI 20.3-30.2),Charlson合并症指数评分<4、年龄<65岁、女性及低危MDS患者生存显著更优。

要点

  • MDS患者中位OS为25.3个月,合并症负荷(CCI≥4)、高龄、男性及高危MDS与更差生存相关。
  • 20%的MDS患者有既往恶性肿瘤史,其中67%为治疗相关,治疗相关MDS与更差OS相关(HR 1.51,95%CI 1.02-2.23)。
  • 既往恶性肿瘤已缓解者OS与新生MDS相似(25.5 vs 28.3个月),OS与是否接受放疗或化疗无关。

核心结论

  • 多种合并症包括既往恶性肿瘤与MDS患者更短的总生存期相关。

研究设计与样本

  • 基于HemoBase登记库的观察性人群研究,纳入荷兰弗里斯兰省2005至2017年确诊的全部291例MDS患者,随访至2019年6月。

主要发现

  • 291例MDS患者中位OS为25.3个月(95%CI 20.3-30.2)。
  • CCI评分<4、年龄<65岁、女性及低危MDS患者OS显著更优。
  • MDS诊断时处于缓解期的既往恶性肿瘤患者与新生MDS患者中位OS相似(25.5 vs 28.3个月)。

临床怎么用

  • 在MDS患者预后评估中应纳入合并症负荷(如CCI评分)及既往恶性肿瘤史。
  • 对治疗相关或继发性MDS患者应认识到其生存预后更差,可能需要更密切的随访或个体化治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Population-based studies that contain detailed clinical data on patients with myelodysplastic syndrome (MDS) are scarce. This study focused on the real-world overall survival (OS) of MDS patients in association with comorbidities, specifically malignancies. An observational population-based study using the HemoBase registry was performed, including all patients with MDS diagnosed between 2005 and 2017 in Friesland, a Dutch province. Detailed information about diagnosis, patient characteristics, previous treatment of malignancies, and comorbidities according to the Charlson Comorbidity Index (CCI) was collected from electronic health records. Patients were followed up until June 2019. Kaplan-Meier plots and Cox regression analyses were used to study survival differences. In the 291 patients diagnosed with MDS, the median OS was 25.3 months (95% confidence interval [CI], 20.3-30.2). OS was significantly better for patients with CCI score <4, age <65 years, female sex, and low-risk MDS. Fifty-seven patients (20%) had encountered a prior malignancy (excluding nonmelanoma skin cancer), and a majority (38 patients; 67%) were therapy related. Both therapy-related and secondary MDSs were associated with worse OS (hazard ratio, 1.51; 95% CI, 1.02-2.23 and 1.58; 95% CI, 0.95-2.65, respectively), as compared with de novo MDS patients (P = .04). Patients in remission at time of MDS diagnosis had a similar median OS compared with patients with de novo MDS (25.5 vs 28.3 months). This population-based study involving all newly diagnosed MDS patients over a 13-year period in Friesland showed that multiple comorbidities, including previous malignancies, are associated with shorter OS. OS was not related to the use of radiotherapy or chemotherapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rozema J, Hoogendoorn M, Kibbelaar R, et al. Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study. Blood Adv. 2021. PMID: 33656535. doi:10.1182/bloodadvances.2020003381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。